Hamlet Pharma AB: Hamlet Pharma Q2 Interim Report October 2022 – December 2022

torsdag den 23 februari klockan 08:32

Opening remarks During the second quarter of the fiscal year, Hamlet Pharma has made significant progress in its clinical trial program for Alpha1H, a drug candidate in the HAMLET family, as a standalone treatment for bladder cancer patients. The company has also continued its collaboration with Neurochase for the treatment of brain tumors with Alpha1H and its collaboration with Linnane...

Taggar: hamlet, pharma, interim

Läs hela artikeln på Dagens industri

Relaterade nyheter

Hamlet Pharma advertises in major health supplement - published in one of the world's leading international newspapers, The Guardian
Kommuniké från Årsstämman i Hamlet Pharma AB
Svenske Hamlet, 26: Finns en ilska

Mer från Dagens industri

Alzinovas underskott ökar
Medclair vänder till vinst
Easyfill minskar omsättningen – förlusten ökar